Imatinib resistance in chronic myelogenous leukemia: an emerging challenge.

Simple item page
dc.contributor.authorKhandelwal, Aparna
dc.contributor.authorKawatra, Mallika
dc.contributor.authorBhandari, Virendra
dc.contributor.authorYeshwante, Prashant S
dc.date.accessioned2014-12-23T08:32:44Z
dc.date.available2014-12-23T08:32:44Z
dc.date.issued2014-09
dc.description.abstractResistance to imatinib is a significant clinical issue, and the underlying mechanism of this resistance is multifactorial. The efficacy of imatinib in chronic myeloid leukemia (CML) in achieving a high remission rate and improving prognosis has seriously been challenged by the development of mutants of BCR-ABL gene, which resist the action of imatinib, which is a tyrosine kinase inhibitor. We present here a case of a 35-year-old male, a known case of CML on imatinib therapy, the patient eventually landed in blast crisis and succumbed to the disease and secondary infections.en_US
dc.identifier.citationKhandelwal Aparna, Kawatra Mallika, Bhandari Virendra, Yeshwante Prashant S. Imatinib resistance in chronic myelogenous leukemia: an emerging challenge. International Journal of Basic & Clinical Pharmacology. 2014 Sep-Oct ; 3(5): 908-911.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/154160
dc.language.isoenen_US
dc.source.urihttps://www.ijbcp.com/?mno=164870en_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectImatinib resistanceen_US
dc.subjectblast crisisen_US
dc.titleImatinib resistance in chronic myelogenous leukemia: an emerging challenge.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2014v3n5p908.pdf
Size:
395.46 KB
Format:
Adobe Portable Document Format
Description:
Case report
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Basic & Clinical Pharmacology